Filing Details
- Accession Number:
- 0000905148-20-000880
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-12 21:00:18
- Reporting Period:
- 2020-08-11
- Accepted Time:
- 2020-08-12 21:00:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1651431 | Checkmate Pharmaceuticals Inc. | CMPI | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1278411 | S Corey Goodman | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1329161 | J Robert Adelman | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1634632 | L.p. Ii Fund Strategic Global Venbio | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1729408 | Venbio Global Strategic Gp Ii, Ltd. | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1729409 | Venbio Global Strategic Gp Ii, L.p. | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-08-11 | 3,473,374 | $0.00 | 3,473,374 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-08-11 | 200,000 | $15.00 | 3,673,374 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2020-08-11 | 12,500,000 | $0.00 | 1,671,771 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2020-08-11 | 8,753,350 | $0.00 | 1,314,165 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2020-08-11 | 3,644,624 | $0.00 | 487,438 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Billionaire Hedge Funds
